Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 3

Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US

Authors Schumock GT, Gibbons RD, Lee TA, Joo MJ, Valuck RJ, Stayner LT

Published 8 September 2011 Volume 2011:3 Pages 47—52


Review by Single-blind

Peer reviewer comments 2

Glen T Schumock1, Robert D Gibbons2, Todd A Lee1,3,4,6, Min J Joo4, Robert J Valuck5, Leslie T Stayner6
1Center for Pharmacoeconomic Research, and Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA; 2Center for Health Statistics, and Departments of Medicine and Health Studies, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA; 3Center for Management of Complex Chronic Care, Hines VA Hospital, Hines, IL, USA; 4Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA; 5Department of Clinical Pharmacy, School of Pharmacy, University of Colorado, Aurora, CO, USA; 6Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA

Background: The US Food and Drug Administration has issued warnings about a potential link between leukotriene receptor-modifying agents (LTMA) and suicide. These warnings are based on case reports and there is controversy about the association. While spontaneous reporting of suicide-related events attributed to LTMA has risen dramatically, these data may be biased by the warnings. The objective of this study was to explore the relationship between LTMA and suicide deaths using event data preceding the Food and Drug Administration warnings.
Methods: We conducted a mixed-effects Poisson regression analysis of the association between LTMA prescriptions dispensed and suicide deaths at the county level. Counts of suicide deaths in each US county, stratified by race, age group, gender, and year were obtained from the National Center for Health Statistics for the period January 1, 1999 to December 31, 2006. Counts of LTMA prescriptions dispensed in each US county were obtained from IMS Health Incorporated. The model estimated the overall suicide rate conditional on LTMA use, adjusted for age, gender, race, year, and antidepressant utilization. We also assessed the intracounty and intercounty associations.
Results: There were 249,872 suicides in the US between 1999 and 2006, and the annual suicide rate ranged from 11.17 to 11.92 per 100,000 population. There were 118.63, 11.68, and 0.12 million prescriptions dispensed for montelukast, zafirlukast, and zileuton, respectively, between 1999 and 2006. The mean rate of LTMA prescriptions dispensed by county was 42.91 (95% confidence interval [CI] 42.78–43.04), 4.82 (95% CI 4.81–4.84), and 0.05 (95% CI 0.05–0.05) per 1000 for montelukast, zafirlukast, and zileuton, respectively. We found a negative within-county association between the rate of total LTMA prescriptions dispensed and the suicide rate by county (P = 0.0296). This association was primarily driven by montelukast.
Conclusion: Our results, while subject to certain limitations, provide preliminary evidence that the association between LTMA and suicide could be different (ie, reduced risk) than that which might be anticipated based on previous warnings. Patient-level research is needed to understand more clearly the association between LTMA and suicide.

Keywords: suicide, leukotriene-modifying agents, montelukast, drug safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Readers of this article also read:

Value of portal venous system radiological indices in predicting esophageal varices

Gaduputi V, Patel H, Sakam S, Neshangi S, Ahmed R, Lombino M, Chilimuri S

Clinical and Experimental Gastroenterology 2015, 8:89-93

Published Date: 9 February 2015

Comparison of injury incidences between football teams playing in different climatic regions

Orchard JW, Waldén M, Hägglund M, Orchard JJ, Chivers I, Seward H, Ekstrand J

Open Access Journal of Sports Medicine 2013, 4:251-260

Published Date: 5 December 2013

Facial fat grafting with a prototype injection control device

Hetherington HE, Block JE

Clinical, Cosmetic and Investigational Dermatology 2013, 6:201-209

Published Date: 13 September 2013

Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer

Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, Hong PD, Yu DS, Farber IY

International Journal of Nanomedicine 2012, 7:4159-4168

Published Date: 31 July 2012

An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma

Shen M, Gong FM, Pang PF, Zhu KS, Meng XC, Wu C, Wang J, Shan H, Shuai XT

International Journal of Nanomedicine 2012, 7:3319-3332

Published Date: 2 July 2012

Subtle cytotoxicity and genotoxicity differences in superparamagnetic iron oxide nanoparticles coated with various functional groups

Hong SC, Lee JH, Lee J, Kim HY, Park JY, Cho J, Lee J, Han DW

International Journal of Nanomedicine 2011, 6:3219-3231

Published Date: 7 December 2011

Biomimetic component coating on 3D scaffolds using high bioactivity of mesoporous bioactive ceramics

Yun HS, Kim SH, Khang DW, Choi JI, Kim HH, Kang MJ

International Journal of Nanomedicine 2011, 6:2521-2531

Published Date: 21 October 2011

SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor

Domenici F, Bizzarri AR, Cannistraro S

International Journal of Nanomedicine 2011, 6:2033-2042

Published Date: 19 September 2011